by Gertrud U. Rey As of today, SARS-CoV-2 has infected 18.7 million people and caused 700,000 deaths worldwide. The most realistic way to quickly curb the spread of the virus would require daily identification and isolation of individuals who are contagious, a process that is hampered by cumbersome sampling and testing methods with slow turnaround …
Vincent visits Ohio State University (March 2020) and speaks with Shan-Lu, David, Amanda, Mark, Matt, Chris, and Qiuhong about their careers and their work on retroviruses, hepatitis C virus, coronaviruses, paramyxoviruses, and environmental viruses. Click arrow to playDownload TWiV 650 (63 MB .mp3, 105 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv
Daniel Griffin provides a clinical report on COVID-19, followed by a review of the findings that children shed as much SARS-CoV-2 viral RNA from the respiratory tract as older patients, the lineage giving rise to SARS-CoV-2 has been circulating in bats in China for decades, and answers to listener questions. Click arrow to playDownload TWiV 648 …
Among the mountains of false information being peddled during the current pandemic, one of the most offensive is being used to drive opening of schools in the fall: that children do not transmit SARS-CoV-2. The results of multiple studies have shown that this assertion is incorrect. I’ll review two of them here. One study examined …
Daniel Griffin provides a clinical report on COVID-19, followed by a review of the State Department document on the Wuhan BSL-4 laboratory, the report on infection of tigers and lions in the Bronx Zoo, and, answers to listener questions. Click arrow to playDownload TWiV 645 (98 MB .mp3, 163 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes …
TWiV 645: Lions and tigers and zookeepers (oh my) Read More »
by Gertrud U. Rey On July 20, 2020, Oxford University’s Jenner Institute and the pharmaceutical company AstraZeneca reported preliminary results from phase I/II clinical trials assessing the safety and efficacy of a vaccine candidate against SARS-CoV-2. The vaccine candidate, named AZD1222 (referred to in the publication as ChAdOx1 nCoV-19), consists of an adenovirus vector with an …
Preliminary phase I/II results of ChAdOx1 SARS-CoV-2 vaccine Read More »
